201
|
Guo QS, Qin SY, Zhou SF, He L, Ma D, Zhang YP, Xiong Y, Peng T, Cheng Y, Li XT. Unbalanced translocation in an adult patient with premature ovarian failure and mental retardation detected by spectral karyotyping and array-comparative genomic hybridization. Eur J Clin Invest 2009; 39:729-37. [PMID: 19515099 DOI: 10.1111/j.1365-2362.2009.02141.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND There are only three cases of unbalanced translocation (X;1) reported in childhood in the literature, while no such phenotypic information is available in adults. MATERIALS AND METHODS To delineate the phenotype-genotype relationship of unbalanced translocation (X;1) in adulthood, we reported here a 20-year-old female with an unbalanced translocation (X;1) which was determined by spectral karyotyping, array-comparative genomic hybridization and subtelomeric fluorescence in situ hybridization (FISH). RESULTS The phenotype of partial trisomy 1 and partial monosomy X of the present case was much attenuated, including premature ovarian failure, mental retardation, class I obesity, mild dysmorphism and delayed secondary sexual characteristics. The breakpoints of the unbalanced translocation were accurately located at Xq28 and 1q32.1. The large amplification on Chromosome 1 q arm was found to involve 312 genes and the deletion on Chromosome X q arm also involved 141 genes. Overall, genes associated with physiological process (47 genes), cellular process (33), development (23), response to stimulus (1) and reproduction (1) were observed in the amplification on Chromosome 1 q arm. In addition, genes related to physiological process (23 genes), cellular process (13), development (6) and response to stimulus (2) were observed in the large deletion on chromosome X q arm. Late-replication studies revealed the existence of skewed X inactivation in the derivative X chromosome. CONCLUSIONS The phenotype of partial monosomy X and partial trisomy 1q is much attenuated in case of unbalanced translocation (X;1) in adulthood probably owing to skewed X inactivation in derivative X chromosome.
Collapse
Affiliation(s)
- Q S Guo
- Department of Maternal and Fetal Medicine, The Obstetrics & Gynecology Hospital, Fudan University, 419 Fangxie Road, Shanghai, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
202
|
Abraham C, Low D, Sowell R, Grimm C, Gokhroo G, Michaletz-Lorenz M, Ma D, Olsen J, Creach K. INTER-OBSERVER VARIABILITY IN NON-TRANSVERSE SEGMENTATION. Radiother Oncol 2009. [DOI: 10.1016/s0167-8140(12)73080-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
203
|
Ma D, Zhang H, Kennedy B, Parsons T, Olson WC. Antitumor activity of PSMA ADC after progression on docetaxel in a mouse xenograft model of human prostate cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3030 Background: Currently, there are no approved therapies for castration-resistant metastatic prostate cancer that has progressed following docetaxel therapy. Prostate-specific membrane antigen (PSMA) is an attractive target for antibody-targeted therapy of prostate cancer due to its abundant and restricted expression on the surface of prostate cancer cells. We have developed a novel antibody-drug conjugate (ADC) by linking a fully human PSMA monoclonal antibody to monomethylauristatin E (MMAE), a potent tubulin inhibitor. Here, we describe the use of PSMA ADC in a mouse model to treat xenografted human prostate tumors that have progressed following docetaxel therapy. Methods: Nude mice were implanted subcutaneously with 5 x 106 C4–2 human prostate cancer cells. Animals were first randomized to receive weekly intravenous (IV) doses of either 2 mg/kg docetaxel (n = 50) or vehicle (n = 10). Docetaxel significantly reduced tumor growth (p = 0.025) during the initial phase of the study; however, most of the tumors later progressed. When the tumor volume of an animal in the docetaxel group exceeded 400 mm3, the animal was rerandomized to receive continued docetaxel therapy (n = 18) or weekly IV doses of 6 mg/kg PSMA ADC (n = 18). Treatment effects were assessed by measuring tumor volume and overall survival. When tumor volume was assessed to be ≥2,000 mm3, animals would be sacrificed. Results: At 134 days following tumor implantation, the survival rate was 100% for animals in the PSMA ADC treatment group; 94% of these mice had tumor sizes <100 mm3. In the continued docetaxel treatment group, 14 of 18 animals that were sacrificed when their tumors exceeded 2,000 mm3; the survival rate was 22%. Therefore, PSMA ADC treatment significantly shrank tumors and increased overall survival of animals compared to continued docetaxel treatment (p < 0.0001). Conclusions: PSMA ADC had antitumor activity in mice to xenografted human prostate tumors that had progressed following docetaxel treatment. Treatment with PSMA ADC significantly extended survival in this setting. [Table: see text]
Collapse
Affiliation(s)
- D. Ma
- PSMA Development Company, LLC, Tarrytown, NY
| | - H. Zhang
- PSMA Development Company, LLC, Tarrytown, NY
| | - B. Kennedy
- PSMA Development Company, LLC, Tarrytown, NY
| | - T. Parsons
- PSMA Development Company, LLC, Tarrytown, NY
| | - W. C. Olson
- PSMA Development Company, LLC, Tarrytown, NY
| |
Collapse
|
204
|
Ma D, Zhu J, Grigsby P. 55 oral: Utility of FDG-PET in Defining a High Risk GTV for Cervical Cancer. Radiother Oncol 2009. [DOI: 10.1016/s0167-8140(15)34312-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
205
|
Nagy B, Fedonidis C, Photiou A, Wahba J, Paule CC, Ma D, Buluwela L, Nagy I. Capsaicin-sensitive primary sensory neurons in the mouse express N-Acyl phosphatidylethanolamine phospholipase D. Neuroscience 2009; 161:572-7. [PMID: 19327387 PMCID: PMC2724038 DOI: 10.1016/j.neuroscience.2009.03.047] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2009] [Revised: 03/17/2009] [Accepted: 03/17/2009] [Indexed: 01/30/2023]
Abstract
Our previous finding, that the capsaicin- and KCl-induced Ca2+-dependent production of the intra- and intercellular signaling molecule N-arachidonoyl ethanolamine (anandamide) in cultured primary sensory neurons could be abolished and reduced by ∼2/3 by capsaicin-induced degeneration of capsaicin-sensitive neurons, respectively suggests that a major sub-population of capsaicin-sensitive cells together with a group of non-capsaicin-sensitive cells should express enzymes involved in Ca2+-dependent anandamide synthesis. N-acyl phosphotidylethanolamine phospholipase D (NAPE-PLD) is known to be involved in Ca2+-dependent anandamide production. Hence, here, we used reverse transcriptase and quantitative real time polymerase chain reaction to study NAPE-PLD expression in dorsal root ganglia and to clarify the sub-population of cells expressing this enzyme. Cultures prepared from mouse dorsal root ganglia were grown either in the absence or presence of the neurotoxin, capsaicin (10 μM) overnight. We report, that NAPE-PLD is expressed both in dorsal root ganglia and cultures prepared from dorsal root ganglia and grown in the absence of capsaicin. Furthermore, we also report that capsaicin application downregulates the expression of NAPE-PLD as well as the capsaicin receptor, transient receptor potential vanilloid type 1 ion channel, by about 70% in the cultures prepared from dorsal root ganglia. These findings indicate that a major sub-population of capsaicin-sensitive primary sensory neurons expresses NAPE-PLD, and suggest that NAPE-PLD is expressed predominantly by capsaicin-sensitive neurons in dorsal root ganglia. These data also suggest that NAPE-PLD might be a target to control the activity and excitability of a major sub-population of nociceptive primary sensory neurons.
Collapse
Affiliation(s)
- B Nagy
- Department of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, Faculty of Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
| | | | | | | | | | | | | | | |
Collapse
|
206
|
Ma D, Stoica AD, Wang XL. Power-law scaling and fractal nature of medium-range order in metallic glasses. Nat Mater 2009; 8:30-34. [PMID: 19060888 DOI: 10.1038/nmat2340] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2008] [Accepted: 11/03/2008] [Indexed: 05/27/2023]
Abstract
The atomic structure of metallic glasses has been a long-standing scientific problem. Unlike crystalline metals, where long-range ordering is established by periodic stacking of fundamental building blocks known as unit cells, a metallic glass has no long-range translational or orientational order, although some degrees of short- and medium-range order do exist. Previous studies have identified solute- (minority atom)-centred clusters as the fundamental building blocks or short-range order in metallic glasses. Idealized cluster packing schemes, such as efficient cluster packing on a cubic lattice and icosahedral packing as in a quasicrystal, have been proposed and provided first insights on the medium-range order in metallic glasses. However, these packing schemes break down beyond a length scale of a few clusters. Here, on the basis of neutron and X-ray diffraction experiments, we propose a new packing scheme-self-similar packing of atomic clusters. We show that the medium-range order has the characteristics of a fractal network with a dimension of 2.31, and is described by a power-law correlation function over the medium-range length scale. Our finding provides a new perspective of order in disordered materials and has broad implications for understanding their structure-property relationship, particularly those involving a change in length scales.
Collapse
Affiliation(s)
- D Ma
- Neutron Scattering Science Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | | | | |
Collapse
|
207
|
Rios HF, Ma D, Xie Y, Giannobile WV, Bonewald LF, Conway SJ, Feng JQ. Periostin is essential for the integrity and function of the periodontal ligament during occlusal loading in mice. J Periodontol 2008; 79:1480-90. [PMID: 18672999 DOI: 10.1902/jop.2008.070624] [Citation(s) in RCA: 171] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND The ability of the periodontal ligament (PDL) to absorb and distribute forces is necessary for periodontal homeostasis. This adaptive response may be determined, in part, by a key molecule, periostin, which maintains the integrity of the PDL during occlusal function and inflammation. Periostin is primarily expressed in the PDL and is highly homologous to betaig-H3 (transforming growth factor-beta [TGF-beta] inducible gene). Cementum, alveolar bone, and the PDL of periostin-null mice dramatically deteriorate following tooth eruption. The purpose of this study was to determine the role of periostin in maintaining the functional integrity of the periodontium. METHODS The periodontia from periostin-null mice were characterized followed by unloading the incisors. The effect of substrate stretching on periostin expression was evaluated using a murine PDL cell line. Real-time reverse transcription-polymerase chain reaction was used to quantify mRNA levels of periostin and TGF-beta. TGF-beta1 neutralizing antibodies were used to determine whether the effects of substrate stretching on periostin expression are mediated through TGF-beta. RESULTS Severe periodontal defects were observed in the periostin-null mice after tooth eruption. The removal of masticatory forces in periostin-null mice rescue the periodontal defects. Periostin expression was increased in strained PDL cells by 9.2-fold at 48 hours and was preceded by a transient increase in TGF-beta mRNA in vitro. Elevation of periostin in response to mechanical stress was blocked by the addition of 2.5 ng/ml neutralizing antibody to TGF-beta1, suggesting that mechanical strain activates TGF-beta to have potential autocrine effects and to increase periostin expression. CONCLUSION Mechanical loading maintains sufficient periostin expression to ensure the integrity of the periodontium in response to occlusal load.
Collapse
Affiliation(s)
- H F Rios
- Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109-1078, USA.
| | | | | | | | | | | | | |
Collapse
|
208
|
Sanders RD, Ma D, Brooks P, Maze M. Balancing paediatric anaesthesia: preclinical insights into analgesia, hypnosis, neuroprotection, and neurotoxicity. Br J Anaesth 2008; 101:597-609. [PMID: 18796440 DOI: 10.1093/bja/aen263] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Logistical and ethical reasons make conducting clinical research in paediatric practice difficult, and therefore safe and efficacious advances are dependent on good preclinical research. For example, notable advances have been made in preclinical studies of pain processing that correlate well with patient data. Other areas of paediatric anaesthetic research remain in their infancy including mechanisms of anaesthesia and anaesthetic neuroprotection and neurotoxicity. Animal data have identified the potential 'double-edged' sword of administering anaesthetic agents in the young; although these agents can be neuroprotective in certain circumstances, they can be neurotoxic in others. The potential for this toxicity must be balanced against the importance of providing adequate anaesthesia for which there can be no compromise. We review the current state of preclinical research in paediatric anaesthesia and identify areas which require further exploration in order to provide the foundations for well-conducted clinical trials.
Collapse
Affiliation(s)
- R D Sanders
- Department of Anaesthetics, Pain Medicine and Intensive Care, Faculty of Medicine, Imperial College London, London, UK.
| | | | | | | |
Collapse
|
209
|
Huang X, Zhuang L, Cao Y, Gao Q, Han Z, Tang D, Xing H, Zhou J, Ma D. Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71664-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
210
|
Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, Hu Z, Koppiker CB, Nair S, Dawar R, Dhindsa N, Miller ID, Ma D, Lin B, Awasthy B, Perou CM. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer 2008; 98:1327-35. [PMID: 18382427 PMCID: PMC2361717 DOI: 10.1038/sj.bjc.6604322] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2007] [Revised: 02/25/2008] [Accepted: 02/26/2008] [Indexed: 02/07/2023] Open
Abstract
This study examined the pathological complete response (pCR) rate and safety of sequential gemcitabine-based combinations in breast cancer. We also examined gene expression profiles from tumour biopsies to identify biomarkers predictive of response. Indian women with large or locally advanced breast cancer received 4 cycles of gemcitabine 1200 mg m(-2) plus doxorubicin 60 mg m(-2) (Gem+Dox), then 4 cycles of gemcitabine 1000 mg m(-2) plus cisplatin 70 mg m(-2) (Gem+Cis), and surgery. Three alternate dosing sequences were used during cycle 1 to examine dynamic changes in molecular profiles. Of 65 women treated, 13 (24.5% of 53 patients with surgery) had a pCR and 22 (33.8%) had a complete clinical response. Patients administered Gem d1, 8 and Dox d2 in cycle 1 (20 of 65) reported more toxicities, with G3/4 neutropenic infection/febrile neutropenia (7 of 20) as the most common cycle-1 event. Four drug-related deaths occurred. In 46 of 65 patients, 10-fold cross validated supervised analyses identified gene expression patterns that predicted with >or=73% accuracy (1) clinical complete response after eight cycles, (2) overall clinical complete response, and (3) pCR. This regimen shows strong activity. Patients receiving Gem d1, 8 and Dox d2 experienced unacceptable toxicity, whereas patients on other sequences had manageable safety profiles. Gene expression patterns may predict benefit from gemcitabine-containing neoadjuvant therapy.
Collapse
Affiliation(s)
- P K Julka
- Department of Radiotherapy and Oncology, AIIMS, New Delhi 110029, India
| | - R T Chacko
- Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu 632004, India
| | - S Nag
- Department of Medical Oncology, HCJMRI, Pune, Maharashtra 411001, India
| | - R Parshad
- Department of Radiotherapy and Oncology, AIIMS, New Delhi 110029, India
| | - A Nair
- Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu 632004, India
| | - D S Oh
- Departments of Genetics and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Z Hu
- Departments of Genetics and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - C B Koppiker
- Department of Medical Oncology, HCJMRI, Pune, Maharashtra 411001, India
| | - S Nair
- Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu 632004, India
| | - R Dawar
- Department of Radiotherapy and Oncology, AIIMS, New Delhi 110029, India
| | - N Dhindsa
- Eli Lilly and Company (India) Pvt. Ltd., Gurgaon, Haryana 122001, India
| | - I D Miller
- Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZD, UK
| | - D Ma
- Eli Lilly and Company, Indianapolis, IN 46285, USA
| | - B Lin
- Eli Lilly and Company, Indianapolis, IN 46285, USA
| | - B Awasthy
- Health Care Global Enterprises, Curie Centre of Oncology, St John's Hospital Campus, Koramangala, Bangalore 560034, India
| | - C M Perou
- Departments of Genetics and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| |
Collapse
|
211
|
Huang J, Shi T, Ma T, Zhang Y, Ma X, Lu Y, Song Q, Liu W, Ma D, Qiu X. CCDC134, a novel secretory protein, inhibits activation of ERK and JNK, but not p38 MAPK. Cell Mol Life Sci 2008; 65:338-49. [PMID: 18087676 DOI: 10.1007/s00018-007-7448-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In this study, we report a novel gene, CCDC134 (coiled-coil domain containing 134), that encodes a secretory protein that can inhibit the MAPK pathway as a novel human MAPK-regulating protein. The CCDC134 mRNA contains 1280 nucleotides, encoding a protein of 229 amino acids. CCDC134 is a classical secretory protein. Expression profile analysis by Northern blot, RT-PCR, immunohistochemistry and Western blot reveals that CCDC134 is widely expressed in normal adult tissues, tumor tissues and cell lines. Functional investigation reveals that overexpression of CCDC134 and its purified protein significantly inhibit transcriptional activity of Elk1 and phosphorylation of Erk and JNK/SAPK but not p38 MAPK. Conversely, specific siRNA against CCDC134 activates Elk1 transcriptional activity and promotes Erk and JNK/SAPK phosphorylation. These results clearly indicate that CCDC134 is a novel member of the secretory family and down-regulates the Raf-1/MEK/ERK and JNK/ SAPK pathways.
Collapse
Affiliation(s)
- J Huang
- School of Basic Medical Science, Peking University Health Science Center, Beijing, People's Republic of China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
212
|
Muchemwa FC, Ma D, Inoue Y, Curtin JA, Bastian BC, Ihn H, Kageshita T. Constitutive activation of the phosphatidyl inositol 3 kinase signalling pathway in acral lentiginous melanoma. Br J Dermatol 2007; 158:411-3. [PMID: 17999703 DOI: 10.1111/j.1365-2133.2007.08292.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
213
|
Diao Y, Ma D, Wen Z, Yin J, Xiang J, Li M. Using pseudo amino acid composition to predict transmembrane regions in protein: cellular automata and Lempel-Ziv complexity. Amino Acids 2007; 34:111-7. [PMID: 17520325 DOI: 10.1007/s00726-007-0550-z] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2007] [Accepted: 03/21/2007] [Indexed: 10/23/2022]
Abstract
Transmembrane (TM) proteins represent about 20-30% of the protein sequences in higher eukaryotes, playing important roles across a range of cellular functions. Moreover, knowledge about topology of these proteins often provides crucial hints toward their function. Due to the difficulties in experimental structure determinations of TM protein, theoretical prediction methods are highly preferred in identifying the topology of newly found ones according to their primary sequences, useful in both basic research and drug discovery. In this paper, based on the concept of pseudo amino acid composition (PseAA) that can incorporate sequence-order information of a protein sequence so as to remarkably enhance the power of discrete models (Chou, K. C., Proteins: Structure, Function, and Genetics, 2001, 43: 246-255), cellular automata and Lempel-Ziv complexity are introduced to predict the TM regions of integral membrane proteins including both alpha-helical and beta-barrel membrane proteins, validated by jackknife test. The result thus obtained is quite promising, which indicates that the current approach might be a quite potential high throughput tool in the post-genomic era. The source code and dataset are available for academic users at liml@scu.edu.cn.
Collapse
Affiliation(s)
- Y Diao
- College of Chemistry, Sichuan University, Chengdu, Sichuan, China
| | | | | | | | | | | |
Collapse
|
214
|
Chen Y, Li G, Yin S, Xu J, Ji Z, Xiu X, Liu L, Ma D. Genetic polymorphisms involved in toxicant-metabolizing enzymes and the risk of chronic benzene poisoning in Chinese occupationally exposed populations. Xenobiotica 2007; 37:103-12. [PMID: 17178637 DOI: 10.1080/00498250601001662] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Benzene is a recognized haematotoxin and leukaemogen, but its mechanism of action and the role of genetic susceptibility are still unclear. Cytochrome P450 2E1 (CYP2E1) and myeloperoxidase (MPO) are involved in benzene activation; and NAD (P)H:quinine oxidoreductase 1 (NQO1), glutathione S-transferase theta 1 (GSTT1) and glutathione S-transferase mu 1 (GSTM1) participate in benzene detoxification. The common, well-studied single-nucleotide polymorphisms (SNPs) were analysed in these genes drawn from the toxicant-metabolizing pathways. A total of 100 workers with chronic benzene poisoning (CBP) and 90 controls were enrolled in China. There was a 2.82-fold (95% CI = 1.42-5.58) increased risk of CBP in the subjects with the NQO1 609C > T mutation genotype (T/T) compared with those carrying heterozygous (C/T) and wild-type (C/C). The subjects with the GSTT1 null genotype had a 1.91-fold (95% CI = 1.05-3.45) increased risk of CBP compared with those with GSTT1 non-null genotype. There was no association of CYP2E1 and MPO genotype with CBP. A three genes' interaction showed that there was a 20.41-fold (95% CI = 3.79-111.11) increased risk of CBP in subjects with the NQO1 609C > T T/T genotype and with the GSTT1 null genotype and the GSTM1 null genotype compared with those carrying the NQO1 609C > T C/T and C/C genotype, GSTT1 non-null genotype, and GSTM1 non-null genotype. The study provides evidence of an association of a gene-gene interaction with the risk of CBP.
Collapse
Affiliation(s)
- Y Chen
- College of Public Health, XinJiang Medical University, Urumqi, China.
| | | | | | | | | | | | | | | |
Collapse
|
215
|
Abstract
BACKGROUND Platelet activation is implicated in thrombotic disorders, but has not been described in acute clinical pulmonary embolism (PE). OBJECTIVES To investigate the natural history of platelet activation in PE and associated markers of inflammation, thrombosis and cardiac dysfunction. METHODS Thirty-five consecutive patients (age 62 +/-17 years) with acute PE were prospectively enrolled and followed for 6 months. Platelet activation was assessed by flow cytometry [measuring expression of platelet P-selectin, conformational activation of glycoprotein IIb/IIIa complex (PAC-1) and formation of platelet-leukocyte complexes] and by plasma soluble P-selectin. Platelet activation, right ventricular (RV) function (assessed as RV ejection area by transthoracic echocardiography), D-dimer and high-sensitivity C-reactive protein (hs-CRP) were measured at presentation and repeated over 6 months follow-up. RESULTS Soluble P-selectin (56 +/-19 ng mL(-1), anovaP < 0.0001) and PAC-1 (1.5 +/- 1.8%, anovaP = 0.005) were mildly but significantly increased in patients with acute PE relative to healthy young men (soluble P-selectin 33 +/- 13 ng mL(-1), P < 0.001; PAC-1 binding 0.5 +/- 0.6%, P < 0.01) and age-matched controls (soluble P-selectin 31 +/- 9 ng mL(-1), P < 0.001; PAC-1 binding 0.4 +/-0.4%, P < 0.05). Platelet P-selectin expression and platelet-leukocyte complexes were not increased during acute PE. Echocardiographic RV ejection area correlated inversely with soluble P-selectin (r = -0.47, P = 0.007) and positively with platelet P-selectin (r = 0.49, P = 0.0007), suggesting P-selectin is shed from activated platelets in proportion to the severity of RV dysfunction. Elevated soluble P-selectin, D-dimer and hs-CRP demonstrated a time-dependent return to normal during 6 months follow-up. CONCLUSION Platelet activation is evident after acute PE. Platelet activation correlates with the severity of RV dysfunction, and can persist for several months after acute PE.
Collapse
Affiliation(s)
- T Chung
- Department of Cardiology, Concord Hospital, ANZAC Research Institute, University of Sydney, Sydney, Australia
| | | | | | | | | | | | | | | |
Collapse
|
216
|
Martin JL, Ma D, Hossain M, Xu J, Sanders RD, Franks NP, Maze M. Asynchronous administration of xenon and hypothermia significantly reduces brain infarction in the neonatal rat. Br J Anaesth 2007; 98:236-40. [PMID: 17210733 DOI: 10.1093/bja/ael340] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Neonatal asphyxia causes long-term neurological and behavioural impairment in the developing brain. Concurrent administration of xenon and hypothermia synergistically reduces long-term damage in a rat model of neonatal asphyxia. This study sought to investigate whether asynchronous administration of xenon and hypothermia is capable of combining synergistically to provide neuroprotection. METHODS Seven-day-old rats were subjected to right common carotid artery occlusion followed by 90 min hypoxia with 8% oxygen. After a 1 h recovery period, rats received asynchronous administration of mild hypothermia (35 degrees C) and xenon (20%) with a 1 or 5 h gap between interventions, xenon (20%) alone, or mild hypothermia (35 degrees C) alone. Infarct volume in the brain was measured 4 days after injury. RESULTS Administration of hypothermia or xenon alone, 1 and 6 h after the hypoxic ischaemic insult, respectively, provided no neuroprotection. Asynchronous administration of xenon and hypothermia at a 1 h interval produced a significant reduction in infarct volume [93 (7) vs 74 (8); P < 0.05]. Reduction in infarct volume was also present when hypothermia and xenon were asynchronously administered with an intervening gap of 5 h [97 (5) vs 83 (3); P < 0.05]. CONCLUSIONS This finding provides a rationale for investigating the combined use of hypothermia and xenon in a progressive manner for the management of neonatal asphyxia. Thus, hypothermia can be administrated at the site of delivery and xenon can be administered later.
Collapse
Affiliation(s)
- J L Martin
- Department of Anaesthetics, Pain Medicine, and Intensive Care, Imperial College London, London, UK
| | | | | | | | | | | | | |
Collapse
|
217
|
Chung T, Connor D, Joseph J, Emmett L, Mansberg R, Ma D, Kritharides L. Shedding of P-selectin from Activated Platelets Correlates with the Severity of Right Ventricular Dysfunction During Acute Pulmonary Embolism. Heart Lung Circ 2007. [DOI: 10.1016/j.hlc.2007.06.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
218
|
Zang S, Ji C, Qu X, Dong X, Ma D, Ye J, Ma R, Dai J, Guo D. A study on Notch signaling in human breast cancer. Neoplasma 2007; 54:304-10. [PMID: 17822320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Breast cancer is one of the leading causes of cancer death in women. The Notch family of proteins plays crucial roles in determining cell fates such as proliferation, differentiation and apoptosis. A role for Notch signaling in human breast cancer has been suggested by the development of adenocarcinomas in the murine mammary gland. However, it is not clear currently whether Notch signaling is frequently expressed and activated in breast cancers. Here we show that Notch signaling is overexpressed and highly activated in breast cancers. More significantly, the attenuation of Notch signaling by gamma-secretase inhibitor can inhibit the proliferation of breast cancer cells by both causing cell cycle arrest and apoptosis. Thus, targeting Notch signaling may be of therapeutic value in breast cancers.
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing
- Amyloid Precursor Protein Secretases/antagonists & inhibitors
- Amyloid Precursor Protein Secretases/metabolism
- Apoptosis/physiology
- Basic Helix-Loop-Helix Transcription Factors/genetics
- Basic Helix-Loop-Helix Transcription Factors/metabolism
- Breast/metabolism
- Breast/pathology
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Calcium-Binding Proteins/genetics
- Calcium-Binding Proteins/metabolism
- Cell Cycle/physiology
- Cell Line, Tumor
- Cell Proliferation
- Homeodomain Proteins/genetics
- Homeodomain Proteins/metabolism
- Humans
- Intercellular Signaling Peptides and Proteins/genetics
- Intercellular Signaling Peptides and Proteins/metabolism
- Membrane Proteins/genetics
- Membrane Proteins/metabolism
- Protease Inhibitors/pharmacology
- Proto-Oncogene Proteins/genetics
- Proto-Oncogene Proteins/metabolism
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- RNA, Neoplasm/genetics
- RNA, Neoplasm/metabolism
- Receptor, Notch1/genetics
- Receptor, Notch1/metabolism
- Receptor, Notch3
- Receptor, Notch4
- Receptors, Notch/genetics
- Receptors, Notch/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Serrate-Jagged Proteins
- Signal Transduction
- Transcription Factor HES-1
- Up-Regulation
Collapse
Affiliation(s)
- S Zang
- Department of Hematology, Qilu Hospital, Shandong University, Jinan, P. R. China
| | | | | | | | | | | | | | | | | |
Collapse
|
219
|
He G, Wang J, Ma D. This Paper Has Been Withdrawn.Highly Convergent Route to Cyclopeptide Alkaloids. Total Synthesis of Ziziphine N. Org Lett 2006. [DOI: 10.1021/ol062639z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
220
|
Chan DC, Chen VJ, Zhang Z, Helfrich B, Hirsch FR, Ma D, Bunn PA. Studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancer models. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17114] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17114 Background: Gemcitabine (GEM) is a deoxycytidine analog that inhibits DNA synthesis. Pemetrexed (ALIMTA, PEM) is a novel antifolate inhibiting multiple enzymes targets, including thymidylate synthase (TS). This study aimed at evaluating the antitumor effects of these antimetabolites against NSCLC and SCLC tumor models. Methods: In vitro growth inhibition (IC50) studies were done by 6-days MTT assays against a panel of 20 NSCLC and 17 SCLC cell lines. In vivo studies used only NSCLC H2122 tumor line, implanted either subcutaneously in athymic nude mice or orthotopically in athymic nude rats. Drugs were given via the ip route at the designated schedules. Results: Against NSCLC and SCLC cell lines, the averaged IC50s of GEM were 0.015 ± 0.008 μM and 0.055 ± 0.04 μM respectively. The corresponding averaged IC50s for PEM were 0.65 ± 0.2 μM and 0.091±0.018 μM respectively. When H2122 tumors reached 50–100mg, mice were treated with 10 daily doses of PEM at 100, 200 and 300 mg/kg, or three doses of GEM every 4 days at 30, 60 and 120 mg/kg. PEM delayed tumor growth by 12 to 18 days, and GEM delayed by 10 to 14 days, relative to vehicle control. Results of three combination regimens with GEM (30 mg/kg) and PEM (100 mg/kg) were: (1) GEM → PEM gave intermediate activities between the two single agents, but was toxic to animals; (2) PEM and GEM given concurrently were more active than single agents alone and delayed tumor growth by 12 days with some toxic side effects; (3) PEM → GEM was better than the single agents alone, and delayed tumor growth by ∼14 days without toxicity. Athymic nude rats bearing orthotopic H2122 tumors given PEM daily at 50, 100 and 200 mg/kg for 21 days had significantly prolonged survival, but not in a dose-dependent manner. PEM at 50 mg/kg was more effective than doses at 100 or 200 mg/kg. GEM was toxic to nude rats due to poor plasma deamination of GEM. Conclusions: In vitro, PEM was more potent against SCLC than NSCLC cell lines, but GEM had similar activities against all lung lines tested. Studies of H2122 xenografts in rodent supported PEM → GEM as the preferred sequence for the combined administration of these two drugs. [Table: see text]
Collapse
Affiliation(s)
- D. C. Chan
- University of Colorado Cancer Center, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - V. J. Chen
- University of Colorado Cancer Center, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - Z. Zhang
- University of Colorado Cancer Center, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - B. Helfrich
- University of Colorado Cancer Center, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - F. R. Hirsch
- University of Colorado Cancer Center, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - D. Ma
- University of Colorado Cancer Center, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - P. A. Bunn
- University of Colorado Cancer Center, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
221
|
Eismann U, Oberschmidt O, Ehnert M, Fleeth J, Lüdtke F, Struck S, Schulz L, Blatter J, Ma D, Hanauske A. Thymidylate synthase gene expression in solid tumors predicts for response to pemetrexed in vitro. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13058] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13058 Background: Pemetrexed (P) is a novel antifolate which targets thymidilate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). The aim of the present study was to identify gene expression thresholds for these enzymes in human tumor specimens in order to separate P-sensitive from P-resistant patients. Methods: Soft-agar cloning assays were performed on freshly biopsied tumor cells exposed one hour to clinically achievable concentrations of P. In parallel, RNA was isolated, transcribed to cDNA and subsequently used for multiplex real-time PCR. Gene expression data were normalized against beta-actin transcripts followed by correlation against cloning assay results. Iterative calculations (fourfold analysis) were done for each enzyme separately to find the best cutoff for prediction of sensitivity to P. Results: Sensitive and resistant tumor samples were statistically significant different in gene expression of TS, DHFR, and GARFT (p < 0.003). 81% of all tumors with a TS copy number < 144 (related to 104 copies β-actin) were sensitive to P in vitro. (specificity = 0.69; chi2 = 14.14). Statistical tests demonstrated that gene expression of TS, DHFR, and GARFT are dependent variables and that TS transcription is the leading variable. The combination of TS, DHFR, and GARFT expression data was not superior to TS alone. Conclusions: TS expression is the most meaningful predictor for sensitivity (≤ 144 copies) or resistance (> 144 copies) to Pemetrexed in fresh tumor tissue. This observation forms a rationale for clinical trials using TS expression as predictor for clinical response. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- U. Eismann
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - O. Oberschmidt
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - M. Ehnert
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - J. Fleeth
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - F. Lüdtke
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - S. Struck
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - L. Schulz
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - J. Blatter
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - D. Ma
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - A. Hanauske
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
222
|
Oh DS, Carey LA, Fan C, Sawyer L, Hu Z, Ma D, Perou C. Expression profiles can predict both general chemotherapy and gemcitabine-specific responses in breast cancer patients receiving neoadjuvant therapy. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10008 Background: The identification of markers predictive of neoadjuvant chemotherapy response would be an important advance. Therefore, we sought to identify gene expression profiles predictive of neoadjuvant response and evaluated their drug specificity. Methods: DNA microarray analysis was performed on pre-treatment core biopsies from two different locally advanced breast cancer patient sets receiving neoadjuvant chemotherapy; the first set (L9819) was treated with 4 cycles of doxorubicin + cyclophosphamide (AC) followed by 4 cycles of paclitaxel (T) or paclitaxel + trastuzumab (TH). The second patient set (S329) received 4 cycles of gemcitabine + doxorubicin followed by 4 cycles of gemcitabine + cisplatin. Clinical response was based on RECIST criteria. Results: We obtained successful microarrays on 44 (L9819) and 46 (S329) of the patients enrolled. Ten-fold cross-validated supervised analyses separately performed on each dataset identified gene expression patterns that accurately predicted (75–85% accuracy) response (clinical complete responders vs. others) evaluated on those patients that completed all 8 cycles of chemotherapy. The predictive expression patterns from the L9819 trial were significantly enriched for apoptosis genes, while the predictive gene set from the S329 trial was enriched for nucleotide metabolism genes. The L9819 predictor was able to accurately predict (75% accuracy) response for the S329 patients, however, the S329 predictor was not able to predict response on the L9819 trial (50% accuracy). We speculate that the L9819 predictor was able to predict response on the S329 dataset (despite the fact that only doxorubicin was common to both trials) because this profile was enriched for apoptosis genes that may reflect a general mechanism of chemotherapy response/resistance, while the S329 predictor was more tuned to gemcitabine’s specific mechanism of action. Conclusions: This study may provide the means to predict response to AC-T(H) and GA-GC neoadjuvant chemotherapy. The ability of one predictor to work on the other dataset, but not vise versa, suggests that both general chemotherapy and drug specific response profiles may have been identified. [Table: see text]
Collapse
Affiliation(s)
- D. S. Oh
- University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN
| | - L. A. Carey
- University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN
| | - C. Fan
- University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN
| | - L. Sawyer
- University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN
| | - Z. Hu
- University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN
| | - D. Ma
- University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN
| | - C. Perou
- University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
223
|
Llombart-Cussac A, Martin M, Harbeck N, Anghel R, Eniu A, Melemed A, Clark R, Simms L, Kaiser C, Ma D. Randomized, phase II study of two doses of pemetrexed as first-line chemotherapy for locally advanced or metastatic breast cancer (MBC): Clinical results and exploratory pharmacogenomic analysis. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3077] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3077 Background: Pemetrexed, a folate antimetabolite, has shown varied response in MBC, depending on the dose, vitamin supplementation, and patient pre-treatment status. We conducted a randomized, double-blind, phase II study, in patients with locally advanced or MBC to evaluate 2 doses of pemetrexed. Primary objective was to assess the response rates on the 2 arms. Methods: Women with histologic/cytologic diagnosis of breast cancer, evidence of locally recurrent disease or distant metastasis, not amenable to local therapy were eligible. Patients received pemetrexed (600 mg/m2 Arm A; or 900 mg/m2 Arm B), on D1 of a 21-day cycle. All patients received folic acid and vitamin B12 supplementation. Forty-three patients were planned on each arm. Results: Ninety-two patients (median age 57 years, range 33–81) enrolled: 47 on arm A and 45 on arm B. Arms A and B had response rates of 17.0% (95% CI, 7.7%-30.8%), and 15.6% (95% CI, 6.5%-29.5%), median progression free survival times of 4.2 and 4.1 months, and median times to tumor progression (TtTP) of 4.2 and 4.6 months, respectively. On both arms, a median of 6 cycles was delivered. Toxicity was mild (grade 3/4 toxicity on both arms; neutropenia <20%, leucopenia <9%). Primary tumor samples from 49 patients were assessed for 10 folate or pyrimidine metabolism related gene expressions by reverse transcriptase-polymerase chain reaction methodology. Two markers, folypolyglutamate synthase (FPGS) and thymidine phosphorylase (TP), showed significant results. Best response rates and median TtTP for high vs low FPGS expression subgroups were 37.5% vs 10.0% and 8.6 vs 3.0 months. The corresponding results for TP were 27.6% vs 6.3% and 5.4 vs 1.9 months. Conclusions: Efficacy and safety of the two pemetrexed doses were similar; thus, the lower dose (600 mg/m2) is suitable in patients with MBC. Exploratory biomarker analysis suggests efficacy correlation for FPGS and TP. Further evaluation of these markers appears warranted. [Table: see text]
Collapse
Affiliation(s)
- A. Llombart-Cussac
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| | - M. Martin
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| | - N. Harbeck
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| | - R. Anghel
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| | - A. Eniu
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| | - A. Melemed
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| | - R. Clark
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| | - L. Simms
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| | - C. Kaiser
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| | - D. Ma
- Hospital Universitario Arnau Vilanova, Lleida, Spain; Hospital Universitario San Carlos, Madrid, Spain; Frauenklinik der Technischen Universitaet Muenchen, Munich, Germany; Institutul Oncologic, Bucuresti, Romania; Cancer Institute, Cluj-Napoca, Romania; Eli Lilly and Company, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Eli Lilly Canada Inc., Toronto, ON, Canada
| |
Collapse
|
224
|
Nakajima E, Helfrich B, Chan D, Zhang Z, Hirsch FR, Chen V, Ma D, Bunn PA. Enzastaurin a protein kinase Cbeta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13138] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13138 Background: PKCβ is a member of the PKC family of serine-threonine protein kinases involved in tumor cell proliferation and apoptosis. Inhibition of PKCs induced differentiation and enhanced chemotherapy. PKCβ activation is required for tumor-induced angiogenesis. The PKCβ-selective inhibitor enzastaurin, originally developed as an antiangiogenic agent, inhibited tumor cell proliferation in prostate, colon and glioblastoma cell lines in vitro. In NSCLC lines, enhanced phosphorylation and altered PKC expression was demonstrated. In SCLC lines specific PKC isoforms were associated with cisplatin resistance. Methods: The growth inhibitory effects of enzastaruin were evaluated by 6-day MTT assays; the cell cycle effects by FACS analysis; the effects on downstream phophorylated signaling molecules by western blotting. Results: Enzastaurin inhibited the growth of 11 SCLC lines (IC50s 3–10 μM) and 4 NSCLC cell lines (IC50s 3–10 μM). An increase of 7–31% of cells in the G2/M phase of the cell cycle compared to untreated control was observed following 48 hour exposure to the IC50 dose of enzastaurin in both SCLC and NSCLC cell lines. PKCβ has been shown to phosphorylate both GSK3β and Akt. A 24-hour IC50 enzastaurin exposure significantly reduced phosphorylation of GSK3β (Ser9) in both SCLC and NSCLC lines. No changes were observed in phospho-AKT (Thr308) in either SCLC or NSCLC cell lines. Phospho-ribosomal protein S6 (Ser240/244) was also reduced in both SCLC and NSCLC cell lines. Potential synergy was studied between enzastaurin and pemetrexed in SCLC and NSCLC lines and the results were analyzed using the Calcusyn Program by Chou and Talalay. Synergistic (CI <1) to additive interactions were observed between pemetrexed (IC20–70) and enzastaurin (≤ IC50) in both SCLC lines (N = 3) and NSCLC lines (N = 2). Conclusions: We conclude that enzastaruin produces in vitro growth inhibition of SCLC and NSCLC cell lines through inhibition of GSK3β ser9 phosphorylation and has synergistic growth inhibition with pemetrexed. [Table: see text]
Collapse
Affiliation(s)
- E. Nakajima
- University of Colorado, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - B. Helfrich
- University of Colorado, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - D. Chan
- University of Colorado, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - Z. Zhang
- University of Colorado, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - F. R. Hirsch
- University of Colorado, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - V. Chen
- University of Colorado, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - D. Ma
- University of Colorado, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| | - P. A. Bunn
- University of Colorado, Aurora, CO; Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
225
|
Oberschmidt O, Eismann U, Lahn MM, Fleeth J, Lüdtke F, Struck S, Schulz L, Blatter J, Ma D, Hanauske A. In vitro chemosensitivity against enzastaurin correlates with gene expression of IL8 and GSK3-beta. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13046 Background: Enzastaurin (E) is an active antitumoral agent which selectively inhibits the β-isoform of protein kinase C (PKC-β). The compound blocks the enzyme’s ATP-binding site and signal transmission is abrogated resulting in the inhibition of neovascularization. The aim of the present study was to correlate gene expression with in vitro chemosensitivity of freshly explanted human tumor specimens. Such correlations in tumors taken directly from patients will help to rationally design subsequent clinical trials. Methods: Soft-agar colony forming assays were performed on freshly biopsied tumor cells exposed to various concentrations of E. Corresponding pieces of tumor specimens were shock-frozen and prepared for RNA isolation and cDNA generation followed by multiplex real-time PCR experiments. Gene expression data were correlated against cloning assay results. Results: Gene expression data of PKC-β1, PKC-β2, IL8RA, IL8RB, IL8, GSK3-β, and TGF-β were correlated against in vitro chemosensitivity pattern of E from 66 samples. After 1h-drug exposure gene expressions in sensitive versus resistant specimens were statistically significant with p = 0.013 for IL8 [median copy number (mcn): 1881 vs. 694; n = 66] and p = 0.012 for GSK3-beta (mcn: 1.6 vs. 7.0; n = 66). No correlation was detected for PKC-β1, PKC-β2, IL8RA, and IL8RB. Detection of TGF-β failed in most samples. Conclusions: Low expression of GSK3-β and high expression of IL8 correlate statistically significantly with increased in vitro sensitivity to E in freshly explanted human tumors. These findings may help direct further clinical development of this compound. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- O. Oberschmidt
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - U. Eismann
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - M. M. Lahn
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - J. Fleeth
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - F. Lüdtke
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - S. Struck
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - L. Schulz
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - J. Blatter
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - D. Ma
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| | - A. Hanauske
- AK St. Georg, Hamburg, Germany; Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
226
|
Chen G, Zhou J, Gao Q, Huang X, Li K, Zhuang L, Huang M, Xu G, Wang S, Lu Y, Ma D. Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo. Cancer Gene Ther 2006; 13:930-9. [PMID: 16741520 DOI: 10.1038/sj.cgt.7700967] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Screening and identifying molecules target to checkpoint pathways has fostered the development of checkpoint-based anticancer strategies. Among these targets, inhibition of chk2 may induce cell death for tumors whose growth depends on enhanced chk2 activity. However, improvement of the potency and specificity of such therapeutics remains a major challenge. To resolve this problem, we constructed M3, a novel recombinant adenovirus with a 27-bp deletion in E1A CR2 region by which to realize tumor-specific replication, and an 829-bp of antisense chk2 fragment inserted into the E3 coding region. In this design, M3 exploited the native adenovirus E3 promoters to express antisense chk2 cDNA in a viral replication-dependent fashion, and preferentially silenced the chk2 gene in tumor cells. In vitro and in vivo assays confirmed that downregulated chk2 expression induced by M3 infection was tumor-specific and virus replication-dependent. Furthermore, systemic administration of M3 combined with a low dose of cisplatin cured 75% (9/12) of orthotopic hepatic carcinoma mouse models that were otherwise resistant to cisplatin. Our results indicated that the upcoming development in this field would improve the antitumor efficacy and maximize the synergistic effect of oncolytic viruses administered with traditional chemotherapy or radiotherapy.
Collapse
Affiliation(s)
- G Chen
- Cancer Biology Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
227
|
Song Y, Kong B, Ma D, Qu X, Jiang S. Procaspase-3 enhances the in vitro effect of cytosine deaminase-thymidine kinase disuicide gene therapy on human ovarian cancer. Int J Gynecol Cancer 2006; 16:156-64. [PMID: 16445627 DOI: 10.1111/j.1525-1438.2006.00470.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Because the efficacy of genetic prodrug activation therapy (GPAT) using herpes simplex virus thymidine kinase (tk)/ganciclovir (GCV) or Escherichia coli cytosine deaminase (cd)/5-fluorocytosine (5-FC) is not satisfied in early clinical trials and the mechanism of both the GPATs have been shown to lead to the activation of cell apoptotic pathway, we hypothesized that coexpression of procaspase-3, a central downstream executioner of apoptotic pathways, with cd-tk gene leads to enhanced cell death in ovarian cancer cells in vitro. Following transfection with the vectors encoding cd and tk, 5-FC and GCV treatments lead to greater cell death in procaspase-3-expressing clones of 3AO (3AO-caspase-3) than control cells (3AO-pcDNA3), as well as more rapid activation of caspase-3 and more rapid cleavage of poly (adenosine diphosphate-ribose) polymerase (PARP). There is a greater degree of cell apoptotic rate in the procaspase-3-expressing clones than in control cells following the treatment with cd-tk/5-FC + GCV, and apoptosis is the main cell death form. None of these effects is seen following transfection with a control vector that does not encode tk and cd (pBTdel-279). The results strongly suggest that coexpression of procaspase-3 may lead to a significant enhancement of the efficacy of cd-tk/5-FC + GCV, and this strategy would be a novel and promising approach for the treatment of ovarian cancer.
Collapse
Affiliation(s)
- Y Song
- Departments of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China
| | | | | | | | | |
Collapse
|
228
|
Li J, Zhou J, Chen G, Wang H, Wang S, Xing H, Gao Q, Lu Y, He Y, Ma D. Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model. Cancer Gene Ther 2006; 13:266-72. [PMID: 16179930 DOI: 10.1038/sj.cgt.7700899] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Ovarian cancer is one of the most threatening malignant tumors in females due to the frequent occurrence of metastasis that precedes diagnosis. The present study explored the possibility of preventing ovarian cancer metastasis by promoting nm23H1 expression through adeno-associated virus (AAV)-mediated gene transfer. A cell line of high metastatic potential, SW626-M4, was derived by in vivo selection and used to establish an ovarian cancer metastasis model in the mouse. Liver metastasis and animal survival time were measured after transfer of a recombinant adeno-associated viral vector expressing nm23H1 (AAV-nm23H1) into the aforementioned model. Intraperitoneal injection of AAV-nm23H1 into this orthotopic implantation model of ovarian cancer resulted in (1) expression of the exogenous gene in more than 95% of tumor cells in situ in nude mice; (2) a 60% reduction in the number of animals developing liver metastases; and (3) a 35-day prolongation of median survival time compared with the untreated host group. In conclusion, the results support the feasibility of induction of nm23H1 expression through gene transfer as a therapeutic strategy for preventing metastases and prolonging host survival time, and indicate that AAV vectors deserve attention in the design of future gene therapy approaches to achieving long-term expression of curative genes in vivo.
Collapse
Affiliation(s)
- J Li
- Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, PR China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
229
|
Xi L, Chen G, Zhou J, Xu G, Wang S, Wu P, Zhu T, Zhang A, Yang W, Xu Q, Lu Y, Ma D. Inhibition of telomerase enhances apoptosis induced by sodium butyrate via mitochondrial pathway. Apoptosis 2006; 11:789-98. [PMID: 16554963 DOI: 10.1007/s10495-006-5701-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Telomerase activation represents an early step in carcinogenesis. Increased telomerase activity in cervical cancer suggests a potential target for the development of novel therapeutic drugs. The aim of this study is to investigate the impact of telomerase activity on the biological features of HeLa cells and the possible mechanisms of enhanced apoptosis rate induced by sodium butyrate after telomerase inhibition. We introduced vectors encoding dominate negative (DN)-hTERT, wild-type (WT)-hTERT, or a control vector expressing only a drug-resistance marker into HeLa cells. Thus we assessed the biological effects of telomerase activity on telomere length, cell proliferation, chemosensitivity and radiosensitivity. In order to understand the mechanisms in which DN-hTERT enhances the apoptosis induced by sodium butyrate, we detected the release status of cytochrome c and apoptosis inducing factor (AIF) from mitochondria. Ectopic expression of DN-hTERT resulted in inhibition of telomerase activity, reduction of telomere length, decreased colony formation ability, and loss of tumorigenicity in nude mice. Moreover, DN-hTERT transfected HeLa cells with shortened telomeres were more susceptible to multiple chemotherapeutic agents and radiation. WT-hTERT transfected HeLa cells with longer telomeres exhibited resistance to radiation and chemotherapeutic agents. Our data demonstrate that elevated release level of cytochrome c and AIF from mitochondria might contribute to the enhanced apoptosis in DN-hTERT transfected HeLa cells after treatment with sodium butyrate. Inhibition of telomerase might serve as a promising adjunctive therapy combined with conventional therapy in cervical cancer.
Collapse
Affiliation(s)
- L Xi
- Cancer Biology Research Center, TongJi Hospital, TongJi Medical School, Huazhong University of Science & Technology, Wuhan, Hubei 430030, PR China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
230
|
Jia P, Wu S, Li F, Xu Q, Wu M, Chen G, Liao G, Wang S, Zhou J, Lu Y, Ma D. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells. Int J Gynecol Cancer 2006; 15:1042-8. [PMID: 16343180 DOI: 10.1111/j.1525-1438.2005.00260.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Overexpression of breast cancer resistance protein (BCRP) and mitoxantrone (MX) resistance protein can confer resistance to a variety of cytostatic drugs, such as MX, topotecan (TPT), doxorubicin, and daunorubicin. This study investigates the role of BCRP in resistance of ovarian cancer to TPT treatment. We have developed TPT-resistant human ovarian cancer cell line. Intracellular concentration of fluorescent dye rhodamine 123 (Rh123) was measured by flow cytometry. The expression of several membrane transporter proteins including P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and BCRP were determined by reverse transcription-polymerase chain reaction and Western blotting. The Rh123 concentration in parental cells was approximately three times of those in TPT-resistant cells. In contrast to undetectable level of P-gp messenger RNA (mRNA) and minimal level of MRP1 expression in TPT-resistant cells, overexpression of both the BCRP mRNA and the protein was detected in these cells. Introduction of antisense-phosphorothioate oligonucleotide derived from BCRP mRNA into TPT-resistant cells resulted in a significant increase in the concentration of intracellular Rh123. These results suggested a novel mechanism in which a reduced intracellular drug concentration may be mediated by BCRP gene products in human ovarian cancer cells.
Collapse
Affiliation(s)
- P Jia
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
231
|
Kong B, Huang S, Wang W, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Wang B, Cui B, Yang Q. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. Int J Gynecol Cancer 2006; 15:872-7. [PMID: 16174238 DOI: 10.1111/j.1525-1438.2005.00251.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Arsenic trioxide (As(2)O(3)), has been used for centuries in traditional Chinese medicine; it has considerable efficacy in the treatment of relapsed acute promyelocytic leukemia, inducing partial differentiation and promoting apoptosis of malignant promyelocytes. Although a number of studies have demonstrated that As(2)O(3) has potent activity against cell growth in a series of leukemia cell lines, little information is available regarding this compound's effect on cell growth in solid tumor cell lines. In this study, we investigated the effects of As(2)O(3)in vitro on ovarian cancer cell lines sensitive (3AO) and resistant (3AO/CDDP) to cisplatin. The 3-(4,5-dimethy-thiazoyl-2-yl)-2,5-diphenyl-tetrazolium bromide assay was used to evaluate cytotoxicity. Flow cytometric analysis was used to determine the apoptosis, cell cycle distribution. We clearly demonstrated that As(2)O(3) induced cell apoptosis and inhibition of cell growth in both the cell lines. Furthermore, we identified that As(2)O(3)-induced apoptosis involved Fas pathway. As(2)O(3) is an active agent against ovarian cancer cells and could be effective in the clinical treatment of ovarian cancer.
Collapse
Affiliation(s)
- B Kong
- Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, People's Republic of China.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
232
|
Oberschmidt O, Eismann U, Schulz L, Struck S, Blatter J, Lahn MM, Ma D, Hanauske AR. Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro. Int J Clin Pharmacol Ther 2005; 43:603-4. [PMID: 16372535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2023] Open
|
233
|
Eismann U, Oberschmidt O, Ehnert M, Fleeth J, Lüdtke FE, Struck S, Schulz L, Blatter J, Lahn MM, Ma D, Niyikiza C, Paoletti P, Hanauske AR. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors. Int J Clin Pharmacol Ther 2005; 43:567-9. [PMID: 16372519 DOI: 10.5414/cpp43567] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- U Eismann
- Allgemeines Krankenhaus St. Georg, Hamburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
234
|
Abstract
BACKGROUND Some anaesthetic agents exhibit an age-dependent analgesic effect, for example nitrous oxide, which is ineffective in newborn rats. We investigated whether a similar time dependency existed for the responses to the volatile anaesthetic isoflurane. METHODS The analgesic and hypnotic properties of isoflurane at various ages was assessed using four cohorts of Fischer rats aged approximately 7, 16, and 28 days and adults (11-12 weeks old). Intraplantar administration of formalin mimicked inflammatory pain, and its effects were assessed using immunohistochemical (c-Fos staining) and behavioural paradigms. The hypnotic properties of isoflurane were assessed using loss of righting reflex. RESULTS Formalin administration produced a typical nociceptive response observed both behaviourally and immunohistochemically in all age groups; these nociceptive responses were significantly attenuated by isoflurane 0.5% at each age (P<0.05). Interestingly 7-day-old animals showed a significantly more potent hypnotic response than older animals (P<0.01): with adult rats being most resistant to isoflurane induced hypnosis (P<0.05). CONCLUSION In contrast to nitrous oxide, isoflurane is an effective antinociceptive agent in neonatal rats. If the data can be extrapolated to clinical scenarios these results suggest that isoflurane may be analgesic in newborns as well as adult humans. In addition, isoflurane is a potent hypnotic, especially in the very young, which is in contrast to the neonate's relative resistance to anaesthesia as assessed by minimum alveolar concentration.
Collapse
Affiliation(s)
- R D Sanders
- Department of Anaesthetics and Intensive Care, Faculty of Medicine, Imperial College, London, UK
| | | | | | | | | |
Collapse
|
235
|
Gordon RD, Sivarajah P, Satkunarajah M, Ma D, Vizitiu D, Tarling CA, Withers SG, Rini JM. Structural insights into GnT-I substrate recognition and specificity. Acta Crystallogr A 2005. [DOI: 10.1107/s0108767305088914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
236
|
Yang H, Xie W, Bartlam M, Xue X, Yang K, Ma D, Rao Z. Structure-assisted design of inhibitors targeting coronavirus main proteases. Acta Crystallogr A 2005. [DOI: 10.1107/s0108767305089555] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
237
|
Ma D, Hopf CE, Malewicz AD, Fisch D, Gardner JP, Donovan GP, Schülke N, Goeckeler WF, Maddon PJ, Olson WC. Molecular targeting of prostate cancer with cytotoxins and radioisotopes linked to fully human monoclonal antibodies against prostate-specific membrane antigen. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Ma
- PSMA Development Company, LLC, Tarrytown, NY
| | - C. E. Hopf
- PSMA Development Company, LLC, Tarrytown, NY
| | | | - D. Fisch
- PSMA Development Company, LLC, Tarrytown, NY
| | | | | | - N. Schülke
- PSMA Development Company, LLC, Tarrytown, NY
| | | | | | - W. C. Olson
- PSMA Development Company, LLC, Tarrytown, NY
| |
Collapse
|
238
|
Ma D, Parikh P, Lu W, Nystrom M, Hubenschmidt J, Wahab S, Singh A, Botero A, Myerson R, Low D. SU-FF-J-121: Patterns of Intraabdominal Organ Motion as Measured by Quantitative 4D CT. Med Phys 2005. [DOI: 10.1118/1.1997667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
239
|
Jin E, Ma D, Liang Y, Ji A, Gan S. MRI findings of eosinophilic myelomeningoencephalitis due to Angiostrongylus cantonensis. Clin Radiol 2005; 60:242-50. [PMID: 15664579 DOI: 10.1016/j.crad.2004.05.012] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2004] [Revised: 04/26/2004] [Accepted: 05/04/2004] [Indexed: 10/25/2022]
Abstract
AIM To study the imaging characteristics of eosinophilic myelomeningoencephalitis due to Angiostrongylus cantonensis using magnetic resonance imaging (MRI). MATERIALS AND METHODS Seventeen MRI examinations of the brain and spinal cord in five patients with angiostrongyliasis cantonensis of the central nervous system were performed. The final diagnosis was based on typical clinical symptoms, results of blood and cerebrospinal fluid (CSF) tests, and the presence of nematode larvae in the CSF. The sequential MRI follow-up examinations were carried out at a different stage for every patient from 1 to 28 weeks after the onset of symptoms. The features of the lesions in the brain, spinal cord, meninges and nerve roots on MRI were studied, moreover, the development of the lesions was analysed on follow-up MRI. RESULTS Abnormalities were demonstrated on MRI in all five cases. They included three cases of meningoencephalitis, one case of encephalitis and one myelomeningitis. The locations and appearances of the lesions were as follows: (1) brain involvement in four cases (including cerebrum in four, cerebellum in two and brain stem in three), and spinal cord involvement in one case. These lesions were diffuse or scattered and appeared as similar or slightly reduced signal intensity on T1-weighted images (T1WI), high signal intensity on T2-weighted images (T2WI) and turbo fluid attenuated inversion recovery pulse sequence (FLAIR) images. After administration of gadolinium chelate (Gd-DTPA), multiple round or oval enhancing nodules, with diameters ranging from 3 to 10 mm, were seen on T1WI, a few lesions appeared as stick-shaped enhancement whose longest measurement was 14 mm. Diffuse or local oedema around the lesion could be seen. (2) Meningeal involvement in four cases, a case of ependymal involvement and a case of nerve root involvement were among them. These lesions appeared as linear or nodular enhancement of the leptomeninges and ependyma, as well as nerve root enhancement. (3) There was a mild ventricular enlargement in two cases. On follow-up MRI lesions were most severe from the 5th week to the 8th week and it took at least 4-8 weeks (1-2 months) for a lesion to resolve completely, the resolution of larger lesion needed more than 22 weeks. CONCLUSION Multiple enhancing nodules in the brain and linear enhancement in the leptomeninges were the main features; stick-shaped enhancement was the characteristic sign of the disease on Gd-DTPA enhanced-T1 weighted images.
Collapse
Affiliation(s)
- E Jin
- Department of Radiology, Beijing Friendship Hospital affiliate of Capital University of Medical Sciences, 95 Yong-An Road, Beijing 100050, China.
| | | | | | | | | |
Collapse
|
240
|
Ma D, Jones G. Soft drink and milk consumption, physical activity, bone mass, and upper limb fractures in children: a population-based case-control study. Calcif Tissue Int 2004; 75:286-91. [PMID: 15549642 DOI: 10.1007/s00223-004-0274-y] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2003] [Accepted: 02/20/2004] [Indexed: 10/26/2022]
Abstract
Carbonated beverages have been reported to increase fracture risk in children but the mechanism is unclear. The aim of this population-based case-control study was to investigate the association between soft drink and milk consumption, physical activity, bone mass, and upper limb fractures in children aged 9-16 years. A total of 206 fracture cases and 206 randomly selected individually matched controls were studied. There were 47 hand fractures; 128 wrist and forearm fractures, and 31 upper arm fractures. An interviewer-administered questionnaire was utilized to retrospectively assess last-year physical activity (including television, computer, and video watching) and to recall the average weekly consumption of milk, colas, and total carbonated drinks. Bone mass at the spine, hip, and total body was assessed by dual-energy X-ray absorptiometry (DXA) and metacarpal morphometry. For total fractures, none of the above drink types was significantly different between cases and controls. For wrist and forearm fractures, there was a positive association between cola drink consumption and fracture risk (OR 1.39/unit, 95% CI: 1.01, 1.91). Cola consumption was significantly correlated with television, computer, and video watching (r = 0.20, P = 0.001) but not bone mineral density or milk drinks. After adjustment for television, computer, and video watching and bone mineral density, the association between cola drinks and fracture risk became nonsignificant (OR 1.31/unit, 95% CI: 0.94, 1.83). No association with other fracture sites was observed. In conclusion, cola, but not total carbonated beverage consumption, is associated with increased wrist and forearm fracture risk in children. However, this association is not independent of other factors and appears to be mediated by television watching and bone mineral density but not by decreased milk intake.
Collapse
Affiliation(s)
- D Ma
- Menzies Research Institute, Private Bag 23, 7000, Hobart, Tasmania, Australia
| | | |
Collapse
|
241
|
Oberschmidt O, Eismann U, Ehnert M, Struck S, Blatter J, Lahn M, Ma D, Niyikiza C, Paoletti P, Hanauske A. 487 Correlations of in vitro chemosensitivity of solid tumors to Pemetrexed (P, ALIMTA®) and target gene expression. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80495-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
242
|
Ma D, Gardner JP, Hopf CE, Cohen MA, Donovan GP, Schuelke N, Goeckeler WF, Olson WC. Fully human monoclonal antibodies to PSMA selectively target cytotoxins, radiotoxins and host immunity to prostate cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Ma
- PSMA Development Company LLC, Tarrytown, NY
| | | | - C. E. Hopf
- PSMA Development Company LLC, Tarrytown, NY
| | | | | | | | | | | |
Collapse
|
243
|
Oberschmidt O, Eismann UH, Platzek K, Ehnert M, Blatter J, Lahn MM, Ma D, Clet N, Paoletti P, Hanauske AR. Pemetrexed: Target gene expression in human solid tumors correlates with chemosensitivity patterns. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- O. Oberschmidt
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| | - U. H. Eismann
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| | - K. Platzek
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| | - M. Ehnert
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| | - J. Blatter
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| | - M. M. Lahn
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| | - D. Ma
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| | - N. Clet
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| | - P. Paoletti
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| | - A.-R. Hanauske
- AK St. Georg, Hamburg, Germany; Eli Lilly, Indianapolis, IN
| |
Collapse
|
244
|
Pfreundschuh MG, Trümper L, Ma D, Österborg A, Pettengell R, Trneny M, Shepherd L, Waleswski J, Zinzani PL, Loeffler M. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.6500] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. G. Pfreundschuh
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| | - L. Trümper
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| | - D. Ma
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| | - A. Österborg
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| | - R. Pettengell
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| | - M. Trneny
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| | - L. Shepherd
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| | - J. Waleswski
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| | - P.-L. Zinzani
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| | - M. Loeffler
- Saarland University Medical School, Homburg, Germany; DSHNHL, Homburg, Germany; Australasian Leukaemia and Lymphoma Group ALLG, Sidney, Australia; Swedish Lymphoma Group, Stockholm, Sweden; Britsih National Lymphoma Investigation, London, United Kingdom; Charles University, Prague, Czech Republic; NCI-Canada Lymphoma Group, Homburg, Germany; Polish Lymphoma Group, Warszawa, Poland; Italian Northern Lymphoma Group, Bologna, Italy
| |
Collapse
|
245
|
Moore J, Ma D, Will R, Cannell P, Handel M, Milliken S. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34:241-7. [PMID: 15235579 DOI: 10.1038/sj.bmt.1704570] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Haematopoietic stem cell transplantation (HSCT) has been used recently as an effective therapy in patients with resistant rheumatoid arthritis (RA). Although disease control occurs in the majority of cases, recurrence is common, often coinciding with B-cell reconstitution. We hypothesized that Rituximab, a monoclonal anti-CD20 antibody, would have activity in this group of patients. We treated 10 RA patients (8F:2M, median age 46.5 years), who had recurrent disease post HSCT. All patients received two doses of Rituximab 1 g, 2 weeks apart with no major adverse sequelae and were followed for 12 months. A total of eight out of 10 patients experienced major clinical responses as measured by the American College of Rheumatology (ACR) criteria, with 50-70% improvement in disease parameters. Responses were equivalent to previous responses attained with HSCT. Disease responses were maximal at 4-8 months post Rituximab and correlated with B-cell lymphopenia and a reduction of rheumatoid factor titre. Disease recurrence occurred in 6/9 responders within 12 months and four patients were subsequently retreated, with major responses again attained. This study provides further evidence that B-cell depletion leads to a significant improvement in disease activity in patients with severe RA and provides data for future trials of HSCT and Rituximab therapy.
Collapse
Affiliation(s)
- J Moore
- Haematology Department, St Vincents Hospital, Sydney, NSW, Australia.
| | | | | | | | | | | |
Collapse
|
246
|
Huang H, Jing D, Li Z, Zhou S, Xiao S, Ma D, Zhang R. Analysis of lectin receptors in normal nasal mucosa, nasal polyp, inverted papilloma and papillary adenocarcinoma. J Laryngol Otol 2004; 107:600-2. [PMID: 15125275 DOI: 10.1017/s0022215100123813] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
In order to investigate the changes in glycoprotein structure in the process of cellular differentiation of the nasal mucosa, formalin-fixed, paraffin-embedded biopsy specimens of normal nasal mucosae, nasal polyps, inverted papillomas and papillary adenocarcinomas were analysed by the Avidin Biotin-Peroxidase Complex technique for the demonstration of peanut agglutinin (PNA) receptors, concanavalin ensifomis agglutinin (ConA) receptors, ulex europeaus agglutinin (UEA-I) receptors, wheat germ agglutinin (WGA) receptors, carcino-embryonic antigen (CEA) and keratin. The quantity and distribution of PNA receptors, ConA receptors, UEA-I receptors and CEA were different, in relation to the varying pathological changes. The results suggest that the glycoprotein structure in the cells of the nasal mucosa will change following their differentiation and malignant transformation, which may be helpful in establishing the diagnosis.
Collapse
Affiliation(s)
- H Huang
- Department of Otolaryngology, Changhai Hospital, Shanghai, China
| | | | | | | | | | | | | |
Collapse
|
247
|
Affiliation(s)
- M Lahn
- Divison of Oncology Product Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
248
|
Abstract
Drugs specifically designed to block cellular signalling proteins are currently evaluated as a new way to treat gastrointestinal tumours. One such "new targeted agent" is aprinocarsen, an antisense oligonucleotide that specifically blocks the mRNA of protein kinase C-alpha (PKC-alpha). Blocking PKC-alpha, an important cellular signalling molecule associated with tumour growth, is anticipated to result in tumour cell arrest and achieve clinical benefits. However, it is not known which patients may benefit most from a specific inhibition of PKC-alpha. Past experience with other novel targeted agents suggests that expression of the target molecule is an important factor for the success of such a specific therapy. Therefore, reviewing the specific role of PKC-alpha in various gastrointestinal tumours may contribute to focus the clinical development of selective or specific PKC-alpha inhibitors, such as aprinocarsen, on those patients with a distinctive PKC-alpha expression pattern.
Collapse
Affiliation(s)
- M Lahn
- Divison of Oncology Product Development, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
| | | | | | | |
Collapse
|
249
|
Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer AP, Ma D, Seymour JF, Bradstock K, Joske D, Lynch K, Gathmann I, Hughes TP. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2004; 17:2401-9. [PMID: 14523461 DOI: 10.1038/sj.leu.2403158] [Citation(s) in RCA: 124] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to interferon-alfa plus cytarabine (IFN+AraC). BCR-ABL/BCR% levels were measured by real-time quantitative RT-PCR and were significantly lower for the imatinib-treated patients at all time points up to 18 months, P<0.0001. The median levels for imatinib-treated patients continued to decrease and had not reached a plateau by 24 months. A total of 24 IFN+AraC-treated patients crossed over to imatinib. Once imatinib commenced, the median BCR-ABL/BCR% levels in these patients were not significantly different to those on first-line imatinib for the equivalent number of months. The incidence of progression in imatinib-treated patients, defined by hematologic, cytogenetic or quantitative PCR criteria, was significantly higher in the patients who failed to achieve a 1 log reduction by 3 months or a 2 log reduction by 6 months, P=0.002. A total of 49 patients were screened for BCR-ABL kinase domain mutations. Mutations were detected in two imatinib-treated patients who crossed over from IFN+AraC and both lost their imatinib response. In conclusion, first-line imatinib-treated patients had profound reductions in BCR-ABL/BCR%, which significantly exceeded those of IFN+AraC-treated patients and early measurements were predictive of subsequent response.
Collapse
MESH Headings
- Antimetabolites, Antineoplastic/administration & dosage
- Antineoplastic Agents/administration & dosage
- Benzamides
- Bone Marrow/metabolism
- Cross-Over Studies
- Cytarabine/administration & dosage
- Cytogenetics
- DNA Mutational Analysis
- Fusion Proteins, bcr-abl/blood
- Fusion Proteins, bcr-abl/chemistry
- Fusion Proteins, bcr-abl/genetics
- Humans
- Imatinib Mesylate
- Interferon-alpha/administration & dosage
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Phosphotransferases/chemistry
- Phosphotransferases/genetics
- Piperazines/administration & dosage
- Prognosis
- Protein Structure, Tertiary
- Pyrimidines/administration & dosage
- Treatment Outcome
Collapse
Affiliation(s)
- S Branford
- Institute of Medical and Veterinary Science, Adelaide, South Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
250
|
Chappell LL, Ma D, Milenic DE, Garmestani K, Venditto V, Beitzel MP, Brechbiel MW. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins. Nucl Med Biol 2003; 30:581-95. [PMID: 12900284 DOI: 10.1016/s0969-8051(03)00033-7] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Detailed synthesis of the bifunctional chelating agents 2-methyl-6-(p-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (1B4M-DOTA) and 2-(p-isothiocyanatobenzyl)-5, 6-cyclohexano-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetate (CHX-DOTA) are reported. These chelating agents were compared to 2-(p-isothiocyanatobenzyl)-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (C-DOTA) and 1, 4, 7, 10-Tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N', N", N"'-tris(acetic acid) cyclododecane (PA-DOTA) as their (177)Lu radiolabeled conjugates with Herceptin. In vitro stability of the immunoconjugates radiolabeled with (177)Lu was assessed by serum stability studies. The in vivo stability of the radiolabeled immunoconjugates and their targeting characteristics were determined by biodistribution studies in LS-174T xenograft tumor-bearing mice. Relative radiolabeling rates and efficiencies were determined for all four immunoconjugates. Insertion of the 1B4M moiety into the DOTA backbone increases radiometal chelation rate and provides complex stability comparable to C-DOTA and PA-DOTA while the CHX-DOTA appears to not form as stable a (177)Lu complex while exhibiting a substantial increase in formation rate. The 1B4M-DOTAmay have potential for radioimmunotherapy applications.
Collapse
Affiliation(s)
- L L Chappell
- Radioimmune & Inorganic Chemistry Section, National Cancer Institute/NIH, Bethesda, MD 20892-1002, USA
| | | | | | | | | | | | | |
Collapse
|